The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies
Abstract
The CRISPR/Cas9 system has emerged as a powerful tool for mammalian genome engineering. In basic and translational intervertebral disc (IVD) research, this technique has remarkable potential to answer fundamental questions on pathway interactions, to simulate IVD pathologies, and to promote drug development. Furthermore, the precisely targeted CRISPR/Cas9 gene therapy holds promise for the effective and targeted treatment of degenerative disc disease and low back pain. In this perspective, we provide an overview of recent CRISPR/Cas9 advances stemming from/with transferability to IVD research, outline possible treatment approaches for degenerative disc disease, and discuss current limitations that may hinder clinical translation. Show more
Permanent link
https://doi.org/10.3929/ethz-b-000264153Publication status
publishedExternal links
Journal / series
JOR SpineVolume
Pages / Article No.
Publisher
WileySubject
CRISPR/Cas9; Degenerative disc disease; Intervertebral disc; Low back pain; Targeted genome engineeringOrganisational unit
09597 - Würtz, Karin (SNF-Professur) (ehemalig) / Würtz, Karin (SNF-Professur) (former)
Funding
163678 - Unlocking the mechanisms of mechanotransduction in degenerative disc disease (TRIPDISC) (SNF)
More
Show all metadata
ETH Bibliography
yes
Altmetrics